Kent Lake Capital’s Emergent Biosolutions EBS Stock Holding History

Kent Lake Capital’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$2.05M	Buy	+300,000	New	+$1.29M	0.92%	32

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Kent Lake Capital's EBS Position: Q2 2024 in Review

Kent Lake Capital opened a new position in Emergent Biosolutions (EBS) in Q2 2024: 300,000 shares worth $2.05M. The stake represents 0.92% of the portfolio and ranks #32 among its holdings.

141 funds tracked by Wall St. Rank hold EBS as of Q2 2024.

Kent Lake Capital held 300,000 shares of Emergent Biosolutions worth $2.05M as of Q2 2024.
Emergent Biosolutions was a new Kent Lake Capital position in Q2 2024.
Emergent Biosolutions made up 0.92% of Kent Lake Capital's portfolio in Q2 2024, its #32 holding.
141 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2024.

Based on Kent Lake Capital's 13F filing for Q2 2024, filed 14 Aug 2024.